Diabetes
FDA approves teplizumab to delay type 1 diabetes onset
The FDA has approved teplizumab to delay the onset of type 1 diabetes for both adults and children aged 8 years and older with stage 2 type 1 diabetes, according to an agency press release.
FDA approves second interchangeable insulin glargine biosimilar for patients with diabetes
The FDA approved the second interchangeable insulin glargine biosimilar, Rezvoglar, to improve glycemic control in adults and pediatric patients with diabetes, according to a drug information update from the agency.
VIDEO: Academy’s annual diabetes update provides invaluable information for optometrists
In this Healio video interview, Anthony DeWilde OD, FAAO, director of the tele-eye imaging program at VA Kansas City Health Care, discusses a diabetes update presented by two optometry experts at Academy.
New-onset CKD in diabetes highest among racial, ethnic minorities in US
New-onset chronic kidney disease among U.S. adults with diabetes was highest among racial and ethnic minorities compared with white individuals, according to findings published in The New England Journal of Medicine.
Nighttime outdoor artificial light may increase type 2 diabetes risk
Chronic exposure to outdoor artificial light at night was associated with increased glucose levels, HbA1c and insulin resistance, according to study findings published in Diabetologia.
Diabetes care and education needs to diversify
Susan Weiner, MS, RDN, CDCES, FADCES, talks with Diana Mesa, RD/LDN, CDCES, about barriers to entering the fields of nutrition and diabetes care and education confronted by people from historically marginalized groups.
‘Clear’ reduction in CV, renal outcomes with SGLT2 inhibitors across all high-risk groups
CHICAGO — A meta-analysis of 13 large SGLT2 inhibitor trials, including the recently published EMPA-KIDNEY trial, indicates that the drug class reduces CV and renal outcomes across all high-risk groups, with and without type 2 diabetes.
SGLT2 inhibitors may reduce risk, progression of CKD, AKI regardless of diabetes status
ORLANDO — SGLT2 inhibitors reduce the risk and progression of chronic kidney disease and AKI regardless of diabetes status, according to data presented at ASN Kidney Week.
Virtual diabetes-tailored weight management program benefits adults with type 2 diabetes
SAN DIEGO — A virtual diabetes-tailored weight management program resulted in beneficial and clinically meaningful effects on glucose levels, body weight and diabetes distress among adults with type 2 diabetes.
Infants who breastfeed for shorter duration more likely to have obesity during childhood
SAN DIEGO — Infants exposed to gestational diabetes who breastfeed for less than 6 months and drink sugar-sweetened beverages or natural fruit juice are more likely to have obesity during childhood, according to a presenter.